



**COUNTY OF SAN LUIS OBISPO HEALTH AGENCY
PUBLIC HEALTH DEPARTMENT**

Michael Hill *Health Agency Director*

Penny Borenstein, MD, MPH *Health Officer/Public Health Director*

PROVIDER HEALTH ADVISORY

Date: December 23, 2021

Contact: Rick Rosen, MD, MPH, 805-781-5500, frosen@co.slo.ca.us

Access to Paxlovid and Other COVID-19 Therapies in San Luis Obispo County

Paxlovid™ (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has now received emergency use authorization (EUA) for treating individuals with mild to moderate symptomatic COVID-19 who are at high risk for progression to severe disease. This EUA is for patients 12 years of age and older weighing at least 40 kg.

This is the first treatment for COVID-19 that is in the form of a pill that is taken orally.

The EUA is based on clinical data showing Paxlovid reduced risk of hospitalization or death by 88% when initiated within five days of symptom onset compared to placebo. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 (within five days of symptom onset).

Paxlovid is authorized to be administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Paxlovid is not authorized for initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19 and is not authorized for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

For details and a complete list of drugs that should not be taken in combination with Paxlovid, see the fact sheet for healthcare providers at www.fda.gov/media/155050/download.

Allocation and Limited Supply

The U.S. Department of Health and Human Services (HHS) is allocating the limited supply of Paxlovid to states on an ongoing basis; the initial supply is expected to be very limited, with approximately 6,000 doses allocated for the entire state of California and only 20 initial doses for SLO County.

San Luis Obispo County's first allocation of 20 doses is expected to arrive early in the week of December 27 to the [CVS Pharmacy at 610 West Tefft Street in Nipomo](#) (805-929-2740).

Supply is expected to increase gradually in the weeks ahead. The Public Health Department will provide an update to health care providers as supply increases.

Public Health Department

2191 Johnson Avenue | San Luis Obispo, CA 93401 | (P) 805-781-5500 | (F) 805-781-5543

www.slopublichealth.org

When supplies are limited, patients at highest risk of severe disease should be prioritized.

Other Therapies: Monoclonal Antibodies, Evusheld and Molnupiravir

Monoclonal antibodies remain effective and in adequate supply in SLO County. Patients may visit slopublichealth.org/othertherapies for information about local medical offices providing monoclonal antibodies.

Evusheld, the long-acting anti-SARS-COV-2 monoclonal antibody authorized for use as pre-exposure prophylaxis, is available to SLO County residents via referral from health care providers only. Currently, Central Coast Home Health is the only provider of Evusheld for SLO County residents. Providers may refer eligible patients by calling Brandi Colombo at 805-543-2244, extension 747.

Molnupiravir antiviral medication has also received emergency use authorization for people at high risk for severe illness for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. This medication is **not** currently available in SLO County.

For More Information

FDA Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid:
www.fda.gov/media/155050/download

FDA Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization of Paxlovid:
<https://www.fda.gov/media/155051/download>

Frequently Asked Questions on the Emergency Use Authorization for Paxlovid:
<https://www.fda.gov/media/155052/download>